Martin Rosendale, Chief Executive Officer
Mr. Rosendale joined Cytomedix, Inc. in March 2008 as COO and he was appointed Chief Executive Officer in July 2008. Prior to joining Cytomedix, Mr. Rosendale was Chief Executive Officer of Core Dynamics, Inc. where he managed their Israel based R&D program and initiated U.S. commercial operations for cryobiology and cell lyophilization technologies. Mr. Rosendale has more than 24 years of specialty medical experience. He has held leadership positions for the past 15 years with American Red Cross, SangStat, North American Vaccine and ZLB Bioplasma, in addition to serving on the boards of the Transplant Recipients International Organization and the American Red Cross Biomedical Services, San Jose Region. Mr. Rosendale earned a Bachelor of Science degree in Microbiology from California State University.
Edward L. Field, Chief Operating Officer
Ed Field has been employed at Cytomedix since February 2012. Aldagen since November 2004. Prior to joining Aldagen, Mr. Field was the President and Chief Executive Officer of Inologic, Inc., a private biopharmaceutical company, from 2002 to September 2004. Prior to joining Inologic, from 1999 to 2002, Ed was the President of Molecumetics, Ltd., a drug discovery and development subsidiary of Tredegar Corporation, until its merger with Therics, LLC, a regenerative medicine company. Ed received a Master of Business Administration degree from the University of Virginia's Darden School of Business Administration and a Bachelor of Science degree in Economics from Duke University.
Andrew Maslan, CPA, Chief Financial Officer
Mr. Maslan joined Cytomedix, Inc. in July 2005 and he was appointed Chief Financial Officer in August 2005. Prior to joining Cytomedix, Mr. Maslan served as controller for BioReliance Corporation, he was a principal with GlobeTraders, Inc., and a senior accountant for Providence Laboratory Associates. He began his professional career serving as an auditor with KPMG Peat Marwick, earned a Bachelor of Science degree in Accountancy from Miami University in Oxford, Ohio, and he is a Certified Public Accountant in the State of Maryland.
Peter A. Clausen, Ph.D., Vice President, Business Development
Dr. Clausen joined Cytomedix, Inc. in September 2008 after consulting tothe Company since May2008. Prior to joining Cytomedix, Dr. Clausen was a founding member and Vice President,Research and Development at Marligen Bioscience, a biotechnology company that develops,manufactures and markets innovative products for the life sciences market. Dr. Clausenis a seasoned biochemist with nearly 15 years experience in the biotechnology sector. Dr. Clausen completed his post-doctoral training in the Laboratory of Molecular Oncology at the National Cancer Institute where his research efforts focused in the areas of oncology, hematopoiesis, and gene therapy. Dr. Clausen earned a Bachelor of Science degree in Biochemistry from Beloit College and a Ph.D. in Biochemistry from Rush University.
Carelyn P. Fylling, R.N., M.S.N., C.W.S, C.L.N.C., Vice President, Professional Services
Ms. Fylling joined Cytomedix, Inc. in December 2001. Prior to Cytomedix,Ms. Fylling was recruited to start Curative Health Services, a biotechnology company specializing in the production of autol
ogous platelet releasates for the management of chronic wounds. Since 1986, Ms. Fylling has been instrumental in developing point-of-care PRP systems, conducting clinical/outcome studies in chronic wounds, publishing and presenting on PRP, designing a national wound database, and training physicians and nurses in comprehensive wound management. She currently serves on the Board of Directors of the Association for the Advancement of Wound Care. She received her Bachelor of Science Degreein Nursing from North Park College, Chicago, IL and her Master of Science in Nursing from the University of California, San Francisco, Ca.
Cathryn J. Hope, B.Sc., Vice President, Marketing
Ms. Hope joined Cytomedix, Inc. in January 2012 after consulting to the Company since May 2008. She brings to Cytomedix more than 24 years of International marketing and product commercialization experience in biologics. Prior to joining Cytomedix, Ms. Hope was responsible for the Immunology commercial portfolio at Talecris Biotherapeutics (previously Bayer Biologics). Prior to joining Talecris, Cathryn was Director of Marketing for CSL Behring where she helped launch the US plasma products division of Australian based CSL Limited. Ms. Hope received a Bachelor of Science degree in Immunology from Melbourne University, Australia, and went on to complete a Bachelor of Marketing from the Melbourne Business School/Charles Sturt University, Australia.
David Jorden, Executive Board Director & Investor Relations
Mr. Jorden joined Cytomedix, Inc. in September 2008. He brings to Cytomedix more than 20 years of public and private company investment experience. Prior to joining Cytomedix, Mr. Jorden was responsible for equity portfolio management at Morgan Stanley's Private Wealth Management group and previously served as CFO at Genometrix, Inc., a private genomics/life sciences company. Mr. Jorden serves on the Board of Opexa Therapeutics, Inc., PLx Pharma, Inc., and DLush, a San Diego based deluxe beverage company. Mr. Jorden earned a Master of Management from the Kellogg School of Management at Northwestern University and a BBA from the University of Texas at Austin. He holds both CFA and CPA designations.
Patrick P. Vanek, R.Ph., Vice President, Operations
Patrick Vanek joined Cytomedix, Inc. in July 2010. He brings to Cytomedix more than 30 years of diverse technical and managerial experience in pharmaceuticals and medical devices, specifically Formulation Design, Process Development, QA/QC and Supply Chain/Logistics. Prior to joining Cytomedix, Mr. Vanek spent 12 years at Otsuka America Pharmaceutical, Inc. where he rose through a number of managerial positions to become Vice President of Technical Operations. Prior to that, he held various development/technical management positions at KV Pharmaceutical Corp., Teva Pharmaceuticals USA, Wyeth Laboratories and McNeil Pharmaceutical. Mr. Vanek earned a B.S. in Pharmacy from the Philadelphia College of Pharmacy & Science and is a Registered Pharmacist.